# CHI3L1 Expression in Chordoma: Implications for Immunotherapeutic Intervention

## TL;DR

CHI3L1 is more active in early chordoma tumors and could be a target for new treatments, offering hope for better outcomes in this rare and aggressive cancer.

## Contribution

The study identifies CHI3L1 as a potential biomarker and therapeutic target specific to primary chordoma tumors.

## Key findings

- CHI3L1 expression is elevated in chordoma cells compared to notochordal precursor cells.
- Primary chordoma tumors show higher CHI3L1 expression than recurrent tumors.
- CHI3L1 may play a role in chordoma development and immune evasion.

## Abstract

What are the main findings?
Preliminary qPCR and ELISA indicate elevated CHI3L1 expression in chordoma cells relative to notochordal precursor cells.Transcriptomic analyses of primary and recurrent human chordoma samples suggest that CHI3L1 is differentially expressed in primary tumors compared to their recurrent counterparts, highlighting subtype-specific molecular differences typically obscured in aggregated chordoma datasets.

Preliminary qPCR and ELISA indicate elevated CHI3L1 expression in chordoma cells relative to notochordal precursor cells.

Transcriptomic analyses of primary and recurrent human chordoma samples suggest that CHI3L1 is differentially expressed in primary tumors compared to their recurrent counterparts, highlighting subtype-specific molecular differences typically obscured in aggregated chordoma datasets.

What are the implications of the main findings?
CHI3L1 may serve as a molecular marker of early chordoma development and a potential therapeutic target, particularly in the primary tumor context.These findings underscore the significance of distinguishing chordoma subtypes, which may improve precision in future translational studies and targeted therapy development.

CHI3L1 may serve as a molecular marker of early chordoma development and a potential therapeutic target, particularly in the primary tumor context.

These findings underscore the significance of distinguishing chordoma subtypes, which may improve precision in future translational studies and targeted therapy development.

Chordomas are rare, highly morbid tumors arising from notochordal progenitor cells along the spinal axis, associated with severe neurological complications and high recurrence rates. Their resistance to conventional therapies and limited options beyond surgical resection and high-dose radiation underscore the urgent need for novel therapeutic targets. Publicly available preliminary RNA sequencing data from the Chordoma Foundation identified chitinase-3-like 1 (CHI3L1), a secreted glycoprotein implicated in immune checkpoint regulation and epithelial–mesenchymal transition (EMT), as a promising candidate for chordoma immunotherapy. Yet, the comprehensive function of CHI3L1 in chordoma immune response remains unclear. To evaluate its presence in chordoma, we employed RNA-based analyses alongside enzyme-linked immunosorbent assays (ELISA) on commercially available chordoma cell lines (JHC7, U-CH12, U-CH1, U-CH1-N) and human chordoma tumor specimens. Our results demonstrate elevated CHI3L1 expression in chordoma cells relative to notochordal precursors, with comparative analyses revealing higher CHI3L1 expression in the primary tumor relative to recurrent samples. These findings suggest the potential role of CHI3L1 in chordoma tumorigenesis, emphasizing its relevance as a biomarker and therapeutic target for primary tumors. Future studies are necessary to elucidate the mechanistic role of CHI3L1 in chordoma immune evasion and to explore targeted interventions that may improve patient outcomes in this aggressive cancer.